New book by Larry Connors - Click here to read more
Rediff.com India Ltd. (NASDAQ: REDF | Quote | Chart | News | PowerRating) provides online Internet-based services focusing on India and the global Indian community. Its Web sites consist of interest specific channels relevant to Indian interests, such as cricket; astrology; matchmaker and movies; content on various matters, including news and finance; search facilities; a range of community features, such as email, chat, messenger, and e-commerce; broadband wireless content; and wireless short messaging services to mobile phone subscribers in India. The company also publishes a weekly newspaper, India Abroad, in the United States and Canada. As of March 31, 2007, it had 53.6 million online registered users. The company was founded in 1996. It was formerly known as Rediff Communication Private Limited and changed its name to Rediff.com India Limited in 2000. The company is headquartered in Mumbai, India. With 29.21 million shares outstanding and 416,900 shares declared short as of July 2008, there is no longer a failure to deliver in shares of REDF. According to quarterly data provided by the SEC, there were still 12,482 shares of REDF that were failing-to-deliver as of September 28, 2007.
Syms Corp (NASDAQ: SYMS | Quote | Chart | News | PowerRating) operates a chain of off-price retail stores in the United States. Its stores primarily sell men's tailored clothing and haberdashery; women's dresses, suits, and separates, and accessories; children's apparel; and men's, women's, and children's shoes. The company's stores also offer luggage, domestics, and fragrances. As of March 1, 2008, it operated 33 stores. The company was founded in 1959 and is headquartered in Secaucus, New Jersey. With 14.59 million shares outstanding and 95,700 shares declared short as of July 2008, there is no longer a failure to deliver in shares of SYMS.
Access Pharmaceuticals Inc. (OTCBB: ACCP | Quote | Chart | News | PowerRating) a biopharmaceutical company, together with its subsidiaries, engages in the development of novel therapeutics for the treatment of cancer and supportive care of cancer patients. The company's products include MuGard, a nanopolymer formulation for the management of oral mucositis, a frequent side-effect of cancer therapy. Its lead development candidate for the treatment of cancer includes ProLindac, a Phase II clinical trial candidate for the treatment of ovarian cancer. The company's products under pre-clinical stage comprise Cobalamin, an oral drug delivery technology for the oral delivery of insulin; and Angiolix, a humanized monoclonal antibody, which acts as an anti-angiogenesis factor to cancer cells, notably breast, ovarian, and colorectal cancers. Its products under pre-clinical stage also comprise Prodrax, a non-toxic prodrug that is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent, which combines multiple modes of action to overcome drug resistance; and Cobalamin-mediated targeted delivery. The company has a co-development and sublicense agreement with Virium Pharmaceuticals, Inc. to develop Sodium Phenylbutyrate, a Phase II clinical candidate for the treatment of cancer, autoimmune diseases, and other clinical indications; and a research collaboration with The School of Pharmacy, University of London to develop a synthetic polymer technology to exploit enhanced permeability and retention at tumor sites to accumulate drug and control drug release. Access Pharmaceuticals, Inc. was founded in 1988 and is based in Dallas, Texas. With 17.29 million shares outstanding and 110,600 shares declared short as of July 2008, there is no longer a failure to deliver in shares of ACCP. According to quarterly data provided by the SEC, there were still 14,273 shares of ACCP that were failing-to-deliver as of September 17, 2007.
Genta Inc. (OTCBB: GNTA | Quote | Chart | News | PowerRating) operates as a biopharmaceutical company with a diversified product portfolio that is focused on delivering products for the treatment of patients with cancer. Its research portfolio consists of two programs, DNA/RNA Medicines and Small Molecules. The company's lead compound from its DNA/RNA Medicines program is Genasense (oblimersen sodium) injection that is designed to block the production of a protein, known as Bcl-2, which is a fundamental cause of the inherent resistance of cancer cells to anticancer treatments, such as chemotherapy, radiation, and monoclonal antibodies. Genta Incorporated is recruiting patients to the AGENDA Trial, a global Phase III trial of Genasense in patients with advanced melanoma. Its lead drug in its Small Molecule program is Ganite (gallium nitrate injection), which is marketed in the United States for the treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The company also develops G4544, an oral formulation of the active ingredient in Ganite, which entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. In addition, it is developing tesetaxel, an orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. The company was founded in 1988 and is based in Berkeley Heights, New Jersey. With 36.74 million shares outstanding and 4.34 million shares declared short as of July 2008, there is no longer a failure to deliver in shares of GNTA. According to quarterly data provided by the SEC, there were still 239,625 shares of GNTA that were failing-to-deliver as of September 28, 2007.
New Century Energy Corp. (OTCBB: NCEY | Quote | Chart | News | PowerRating) through its subsidiaries, engages in the acquisition, development, exploration, production, and sale of oil and natural gas in Texas. Its oil and gas properties are primarily located in Matagorda, McMullen, Goliad, and Wharton Counties in Texas. As of December 31, 2007, New Century Energy had proved reserves of 1,613,000 barrels of crude oil and 3.0 billion cubic feet of gas. The company was founded in 1985 and is based in Houston, Texas. With 56.01 million shares outstanding and 169,800 shares declared short as of July 2008, there is no longer a failure to deliver in shares of NCEY. According to quarterly data provided by the SEC, there were still 32,648 shares of NCEY that were failing-to-deliver as of August 24, 2007.
Natural Nutrition Inc. (OTCBB: NTNI | Quote | Chart | News | PowerRating) through its subsidiaries, manufactures health food and nutrition products. It offers sports, nutritional, and natural dietary supplement products. The company sells its products through INII brand, as well as under private label for retailers primarily in the United States, the United Kingdom, the Netherlands, India, Israel, and South Korea. It also owns a website, iNutrition.com, a primary portal through which the company provides nutritional information and products for direct sale to consumers. The company, formerly known as CSI Business Finance, Inc., is headquartered in Houston, Texas. With 37.2 million shares outstanding and 122,900 shares declared short as of July 2008, there is no longer a failure to deliver in shares of NTNI.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,050,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
